Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
(NASDAQ:OTLK),(NASDAQ:OTLKW), ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended […]